There is every indication that if a breakthrough is to come in the understanding of the etiology of one of the major functional psychoses it will occur in the area of the affective disorders (34) . A great deal of investigation has been carried out so far, and each year a better understanding of the psychopathology of these mood disorders seems closer. The evidence to date is mostly indirect but it has allowed for the drawing up of certain guidelines according to which hypotheses can be formulated and tested.
The most popular and widely held hypothesis is that in depression there is a: functional decrease in brain biogenic amines which are chemical substances thought to act as neurotransmitters. In North America the deficiency is considered to be primarily in the catecholamines, namely noradrenaline and dopamine. This catecholamine hypothesis (45, 8) originated from observations that drugs such as reserpine and a-methyldopa, which deplete the brain amines, produce a. small but consistent (approximately 15 per cent) incidence of depression (33) in those who have been on high doses for long periods. Conversely, drugs which are effective in lifting the depressed mood also elevate brain amines -the monoamine oxidase inhibitors by decreasing their rate of metabolism and the tricyclic compounds by inhibiting their re-uptake into presynaptic nerve endings. The specific biochemica.l action of these antidepressant drugs makes interpretation of their effects difficult since they produce elevation of not only the catecholamines but also indoleamines. However, if depression does involve a deficiency of catecholamines, then the most direct way of testing this hypothesis is to correct this deficiency in the form of replacement therapy, after which bene-'Assistant Professor of Psychiatry, McGill University Montreal, Quebec, Canada.
' 'Presented at the Canadian Psychiatric Association Annual Meeting Winnipeg, Manitoba June 1970. Canad. Psyehiat. Ass. J. VoL Hi (1971) ficial clinical effects should be seen. This procedure was carried out but since noradrenaline and dopamine do not pass the blood brain barrier it was necessary to administer their precursor dihydroxy-phenylalanine (DOPA) which can do so. In the initial studies (28) the small amounts of dopa given only produced negative results. However, more recently, workers (9, 10) at the National Institute of Mental Health in Bethesda, Md. showed that large oral doses of L-DOPA (4-8 grams daily) had an antidepressant effect in a small group of retarded patients. Side effects, especially the gastrointestinal disturbances, were high and were thought to be related to the formation of catecholamines in the periphery by the decarboxylation of dopa. The same investigators then used a peripheral decarboxylase inhibitor, a-methyl-dopa hydrazine (MK-485) which does not pass the blood brain barrier and which reduces the peripheral side effects of L-DOPA without interfering with its central action (7) . They found that this combination allowed for one-tenth the amount of L-DOPA to be used -less side effects were noted and the clinical results were the same. The investigators concluded that the administration of L-DOPA is not a generally effective treatment for deprescion. In his discussion of this work, Mc-Clure (38) has suggested the possibility that the small number of retarded depressed patients who respond favourably to this replacement regime of L-DOPA may well be a sub-group with a primary functional deficiency of dopamine rather than noradrenaline, as adherents of the catecholamine hypothesis are inclined to stress.
In Great Britain and Europe serotonin is considered to be the principal biogenic amine which is deficient centrally in psychic depression. Lapin and Oxenkrug (32) from the U.S.S.R. have, in a recent definitive article, reviewed the evidence for this.
Serotonin is a universal substance found in animals and plants. Discovered in Italy by Esparmer (23) , its distribution in the body of an adult is about 10 mg. and is found mostly in the enterochromaffin cells of the intestinal mucosa, in the blood platelets and in certain areas of the brain. The precursor of serotonin is tryptophan which is an essential amino acid. A normal person converts about 1 per cent of metabolized tryptophan into serotonin. This conversion is accomplished in two steps: the enzyme tryptophan hydroxylase adds a hydroxyl group to the tryptophan and 5-hydroxytryptophan is formed, then the enzyme tryptophan decarboxylase removes a carboxyl group and the end product is 5-hydroxytryptamine or serotonin. Serotonin is synthesized in the cells of the central nervous system and is contained in synaptic vesicles of the axon terminals of serotonergic nerves. Exogenous serotonin does not pass the blood brain barrier. The degradation of serotonin is affected by the enzyme monoamine oxidase which removes the amine group and converts serotonin into its urinary excretion products, 5-hydroxyindoleacetic acid (5-HIAA). Small amounts are excreted as conjugates of glucuronic acid and as ethereal sulphates. Oral administration of parachlorophenylalanine, a tryptophan hydroxylase inhibitor, causes selective depletion of brain serotonin; and the destruction of serotonin can be delayed by monoamine oxidase inhibitors.
Serotonin is thought to 'act as a neurohumoral transmitter in certain areas of the central nervous system and large stores are contained in synaptic vesicles of the long descending nerve fibres in the mesencephalon, diencephalon and spinal cord. The brain possesses all the enzymes necessary for synthesis as well as for destruction of serotonin. Nerves liberating serotonin have been identified and called serotonergic or 5-hydroxytryptaminergic nerves. Their function is so far not clearly understood.
The possibility that there is an abnormality in serotonin metabolism in depression was indicated by the finding of Coppen and his associates (15) that urinary tryptamine excretion in depressed subjects is only 50 per cent of normal. Tryptophan, the precursor of 5-HT which passes the blood brain barrier, when given to depressed patients was an effective treatment either alone or combined with monoamine oxidase inhibitors (14, 16) . Ashcroft et al (3) and Dencker et al (22) both noted that 5-HIAA levels in cerebrospinal fluid were reduced in depression and the post mortem studies of the brains of depressed suicides also showed reduced levels of brain 5-HT (46) . A more extensive study (6) of the 5-HT, NA and 5-HIAA contents of the hindbrains of twenty-three depressed people who had committed suicide and twentyeight (controls) who had died from other causes showed that the suicide group had lower levels of 5-HIAA than the control group. The significance of this finding as the investigators point out, is that if the transport of 5-HIAA out of the brain into the blood is the same in both groups, the lowered 5-HlAA levels may indicate that 5-HT synthesis in the brainstem of depressed patients is decreased. If true, this may account for the good therapeutic effects of tryptophan in depression.
The disturbed sleep pattern of depressed patients might also be explained by this indoleamine model since 5-HT has been shown to serve 'as a neurotransmitter in neural pathways mediating sleep in cats and rats (27) . If 5-HT deficiency is produced experimentally by the administration of parachlorophenylalanine (PCPA), insomnia follows but sleep is restored if 5-hydroxytryptophan is administered.
The adrenocortical steroids and their role in depression still remain a mystery, but some evidence has been accumulating regarding their relationship to the biogenic amines. First the relationship between the cortical steroids and serotonin will be discussed. When tryptophan is metabolized only a small amount of it goes to form serotoninmuch more is metabolized by the liver enzyme tryptophan pyrrolase, the synthesis of which is induced by the adrenocorticoids (29) . If there is an increase in cortisol production in depression, and there are many studies to show that there is (37, 25) , then this may increase the amount of pyrrolase which might then divert tryptophan from the serotonin pathway and lead to its deficiency (21) . Many authors have commented upon a possible relationship between pyrrolase and brain 5-RT (35, 18, 32) . In the past, liver biopsy was necessary to determine pyrrolase activity but recently an indirect method which is almost as effective has become available. After a small dose of L-tryptophan the excretion of kynurenine, a metabolite of tryptophan resulting from pyrrolase activity, is almost proportional to pyrrolase activity of biopsied liver material (1).
To determine a direct relationship between pyrrolase activity and brain 5-RT would require determination of brain 5-RT, and this is impossible in humans. Curzon and Green (20) decided to use rats to test whether the high pyrrolase levels are maximal only a few hours after injection of hydrocortisone (30) .
He examined the rat brain 5-RT levels a few hours after a single injection of hydrocortisone and found a significant fall. This fall was maximal six to seven hours after injection and this is in keeping with it being due to increased pyrrolase activity which is at its peak three hours after injection (21) . If a pyrrolase inhibitor such as allopurinol (5 ) or yohimbine (47) is given, hydrocortisone no longer causes a fall in brain 5-RT (21) . Another substance, a-methyltryptophan, which increases pyrrolase activity but by a different mechanism from the adrenocorticosteroids ( 11) was shown to produce a fall of brain 5-RT. It was therefore concluded that high levels of adrenocortical hormones may cause a fall in brain 5-RT due to increased liver pyrrolase activity. The fall in brain 5-RT after hydrocortisone was also accompanied by a comparable fall in 5-RlAA (21) which may indicate decreased 5-RT synthesis, since increased 5-RT breakdown would increase brain 5-RIAA (43) .
Row the fall in brain 5-RT comes about is still not known but one way could be that the increased pyrrolase activity causes a diversion of tryptophan from 5-RT synthesis, which in turn decreases brain 5-RT. Rowever, large peripheral injections of trytophan are required to cause brain 5-RT to increase (36) and it only decreases slowly on a tryptophan free diet in rats (24) , so that a fall of plasma tryptophan alone is unlikely to be responsible for the change of central 5-RT.
Curzon also suggests that kynurenine and other tryptophan metabolites which result from pyrrolase activity cause 5-RT to fall (19) and it may be that these substances are involved in a mechanism by which 5-RT decreases after the administration of hydrocortisone.
Lapin and Oxenkrug (32) summarize the findings by stating that in depression the production of tryptophan pyrrolase by the liver is stimulated by raised blood corticosteroid levels. As a result the metabolism of tryptophan is shunted away from serotonin production 'and towards kynurenine production. Psychic depression may then result from the deficiency of brain serotonin which follows.
Another relationship between the adrenal steroids and the biogenic amines, but of a somewhat different nature, has been proposed. On clinical observation it appeared that physiological amounts of a synthetic steroid, dexamethasone, combined with antidepressant compounds enhanced their effect and speed of action.
There is no direct evidence that cortisol affects the activity of the monoamines in the brain but it does affect this in other organs and there is some indirect evidence which sugges.ts that it may also do so in the brain. Adrenalectomized animals maintained on cortical extract responded to pressor influences in a normal way (2) and those in which the extract was withdrawn had a diminished response ( 12) ; adrenaline or nerve stimulation in such animals increases the demand for cortical hormone. The conclusions drawn from these experiments were that the adrenal cortex is concerned with the capacity of an animal to respond to sympathomimetic substances.
Wurtman and Axelrod (49) demonstrated in animals that adrenal steroids enhanced the activity of the enzyme which converts noradrenaline to adrenaline in the adrenal medulla. Ramey and Goldstein (42) put forward the suggestion that the steroids are permissive for the action of the epinephrines and that in their 'absence the threshold for adrenaline and noradrenaline is raised. They also point out that corticosteroids may play a role in the transmission of impulses in the central nervous system by the 'potentiation of the neurohormones: noradrenaline, serotonin and acetylcholine.
From clinical studies there is also indirect evidence for a close relationship between the action of noradrenaline and the cortical steroids. Kurland and Freedberg (31) demonstrated in normotensive subjects that there was a striking potentiation of the blood pressure response to noradrenaline within twentyfour hours after the administration of adrenocorticotrophic hormone (ACTH) or cortisone, and that the potentiating effect disappeared within thirty-six hours after omission of these agents. They felt their data were consistent with the hypothesis that ACTH increases the pressor response of noradrenaline by the release of C-ll-oxysteroids from the adrenal cortex, and that cortisone alone was equally effective in increasing sensitivity to adrenaline. Cummings and Kort (17) reported a case of Addison's disease in a patient suffering from a psychotic depression who was refractory to twelve ECT's, but after being placed on hydrocortisone he made a dramatic recovery, responding to two ECT's, and then maintained his improvement. Electro convulsive therapy (ECT) may owe its beneficial effects to an alteration in catecholamine and indoleamine metabolism (48, 13, 26) . Whether or not in this instance the steroids facilitated a favourable response to ECT cannot be decided, but such unique instances sometimes provide unexpected results.
There is now a considerable amount of knowledge which indicates that depressive illness per se does not cause adrenal cortical overactivity (44) but that overactivity, if it does occur, is most probably due to the presence of anxiety brought on by environmental stresses. Persky (39) has pointed out that there is a more rapid turnover of cortisol in anxious subjects than normals so that it is possible that the apparent raised plasma levels of adrenosteroids may really be a relative deficiency of the steroid and not an increase. If such a deficit does occur in the peripheral circulation of depressed subjects, it will be reflected in the brain and this shortage of steroid will affect the functioning of the neurohormones. Replacement of physiological amounts of steroid will produce a favourable milieu for the proper functioning of the brain amines, and this is done by the administration of dexamethasone.
With regard to the thyroid gland, Beck (4) in reviewing the literature concluded that in the large number of investigations carried out no significant abnormalities of thyroid function had been demonstrated in depressed patients. However, Prange and his colleagues (40, 41) showed that the addition of a small dose of the thyroid hormone triiodothyronine (T3) to a standard clinical regime of imipramine enhanced the antidepressant action of the drug. They have suggested that the possible mode of action of this clinical observation might be that T3 increases the sensitivity of the central adrenergic receptors to given amounts of noradrenaline. If true, then this action would interact with the known action of imipramine to further promote the propagation of the nerve impulse across the adrenergic synapse.
Brodie and Goodwin (7) suggest that, biochemically, depression is a heterogeneous illness. So far research points to the importance of a functional deficiency of chemicals which are considered to be neurotransmitter substances or modulators of them in producing the clinical picture of depression. Emphasis should be placed, not on an absolute deficiency of any neurohormone, but on the balance in which they interact together to perform efficiently their function of nerve impulse transmission. It is possible that some individuals may be genetically susceptible to a deficiency in catecholamines, others to indoleamines and still others to adrenocorticosteroids or thyroid hormone; or a combination of these substances. Bio-chemically different sub-groups of depressed patients may be identified in the future, such as the retarded subjects of Brodie and Goodwin (7) who appear to be primarily deficient in dopamine and in whom replacement of this specific substance leads to clinical recovery. However, until this happens it would appear that polypharmacy, designed to replace all possible biochemical deficiencies, and not unlike a broad spectrum antibiotic, will be used.
